SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Contemporary collage with a running clock and an arrow. Planning and time management concept.
Regulatory
FDA Outlines Accelerated Review Guidelines in Waning Days of Biden Administration
The program has recently become controversial as a number of high-profile advanced approvals were granted only for the drugs to fail a confirmatory trial later on. Now, the FDA has clearly laid out expectations.
December 6, 2024
 · 
3 min read
 · 
Annalee Armstrong
Businessman holding a dart aiming at the target - business targeting, aiming, focus concept. Art collage.
Bladder cancer
Protara, CG Oncology Tout Promising Bladder Cancer Outcomes
Protara is advancing a cell therapy that triggers both adaptive and innate antitumor immune responses, while CG Oncology’s approach makes use of an oncolytic immunotherapy that preferentially targets cancer cells and proliferates inside them, destroying them from the inside.
December 6, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Eli Lilly's biotechnology center in California
Manufacturing
Lilly Pumps $3B Into Wisconsin Site as Compounders Close In on Tirzepatide
Eli Lilly is aggressively ramping up its manufacturing capacity for tirzepatide as compounding pharmacies continue to challenge an FDA decision to formally end the shortage of the obesity and diabetes drug.
December 6, 2024
 · 
2 min read
 · 
Tristan Manalac
Amgen sign at its headquarters in Thousand Oaks, California, USA.
Manufacturing
Amgen to Add 370 New Jobs in North Carolina With $1B Manufacturing Investment
It is not clear what specifically the new facility will produce, though Amgen could be ramping up its manufacturing capacity as it prepares to enter the obesity space with MariTide.
December 6, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: AstraZeneca building in Gothenburg/iStoc
China
AstraZeneca Names New International Operations Lead Amid Probe on China Exec
Iskra Reic will continue to serve as the pharma’s senior vice president for Vaccines and Immune Therapies as she steps in for Leon Wang, who was detained by Chinese authorities in November.
December 5, 2024
 · 
3 min read
 · 
Tristan Manalac
Funding
Nuvig Ropes in $161M Series B From Big Pharma Players for Autoimmune Indications
California-based biotech Nuvig Therapeutics scooped up $161 million from the investment arms of Sanofi, Bayer, Novo Holdings, BMS and others for its Fc fragment immunomodulator aimed at improving autoimmune dysregulation.
December 5, 2024
 · 
1 min read
 · 
Kate Goodwin
Handshake gesture contemporary collage art. Celebrating success, congratulating for financial and business partnership, job contract deal, mutual friendship and respect. Abstract illustration isolated.
Alzheimer’s disease
GSK Strikes Third Agreement This Week, Leans Further Into Neuro
The Muna partnership will give GSK access to Muna’s MiND-MAP platform, which it will apply to postmortem brain samples to identify potential therapeutic targets for Alzheimer’s disease.
December 5, 2024
 · 
2 min read
 · 
Tristan Manalac
Novartis' office building in Marburg, Germany
Legal
Novartis Loses Appeal to Bar Entresto Generic From U.S. Market
Novartis is seeking to prevent the entry of generics for its blockbuster heart failure drug Entresto, its top-selling asset that brought in more than $6 billion in net global sales last year.
December 5, 2024
 · 
2 min read
 · 
Tristan Manalac
Human hand holding jar with coins. Investment, stock market, trading activity and savings. Contemporary art collage. Concept of business, office, trade market, success, growth. Poster, ad
Drug pricing
Bluebird, Vertex/CRISPR’s SCD Gene Therapies Get New CMS Payment Model
The payment scheme will tie gene therapy payments to improvements in health outcomes—and could potentially boost the uptake of these sickle cell disease treatments.
December 5, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS